NCT00100880 - Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

November 30, 2010

Conditions

Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma

Interventions

DRUG

lenalidomide

Given PO

PROCEDURE

perfusion-weighted magnetic resonance imaging

Correlative studies

PROCEDURE

diffusion-weighted magnetic resonance imaging

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

38105

Pediatric Brain Tumor Consortium, Memphis

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH